FDA Brief

FDA warning letters

A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.

1,117 letters match. Newest first.

  1. Yangzhou Hongshengding Chemical Co., Ltd.

    Yangzhou Hongshengding Chemical refused FDA records requests for its over-the-counter drugs, leading to an import alert.

    High risk
  2. 3B Medical, Inc. dba Reach Health, Inc.

    FDA warns Reach Health over unapproved APAP use change and complaint/CAPA failures.

    High risk
  3. BMC Medical Co., Ltd.

    BMC Medical’s G3X APAP devices were misbranded/adulterated after significant changes without a new 510(k) and an unreported firmware fix.

    High risk
  4. Flax & More Corporation

    FDA warned Flax & More Corporation that its dietary supplements were made under conditions that failed required manufacturing quality rules.

    High risk
  5. Huons Co., Ltd.

    FDA cites Huons in South Korea for data integrity and sterility failures in drug manufacturing.

    High risk
  6. Imu-Tek Animal Health, Incorporated

    FDA warns Imu-Tek Animal Health over unapproved drug claims and manufacturing failures for Colostrom-5 products.

    High risk
  7. Jubilant HollisterStier General Partnership

    FDA found sterile drug manufacturing and investigation failures at Jubilant HollisterStier in Kirkland.

    High risk
  8. Sante Manufacturing Inc.

    Sante Manufacturing’s OTC drugs have significant CGMP violations, including missing identity testing for a high-risk component and inadequate process validation and quality oversight.

    High risk
  9. Pharmathen International S.A.

    FDA warns Pharmathen over inadequate aseptic controls at its Greek plant making sterile drugs for the U.S.

    High risk
  10. ZOLL Medical Corporation

    FDA warned ZOLL Medical after an inspection found quality-system, design-validation, supplier, and reporting failures for defibrillators, ventilators, and electrodes.

    High risk
  11. Happiest Baby, Inc.

    FDA says Happiest Baby marketed unapproved SNOO sleep sacks and hospital bundle and mishandled complaints.

    High risk
  12. Hubei Gedian Humanwell Pharmaceutical Co., Ltd.

    FDA: Hubei Gedian Humanwell API plant has scratched, stained equipment and weak quality unit oversight.

    High risk
  13. Gopaldas Visram & Co., Ltd.

    FDA warns Indian OTC drug maker Gopaldas Visram over talc asbestos testing and data integrity failures.

    High risk
  14. Laboratorios Dr. Collado S.A.

    FDA warns Laboratorios Dr. Collado over inadequate asbestos testing and quality oversight for talc-containing over-the-counter drugs.

    High risk
  15. Revlon Group Holdings, LLC

    FDA cited Revlon's Oxford, NC over-the-counter drug plant for failing to test talc for asbestos and weak quality oversight.

    High risk
  16. Umendra Life Sciences Private Limited

    Umendra Life Sciences, an Indian maker of OTC talc-containing drugs, failed CGMP on talc testing and asbestos control, FDA says.

    High risk
  17. Erkul Kozmetik Sanayi ve Ticaret A.S.

    Erkul Kozmetik failed to test talc in OTC drugs for identity and asbestos, violating manufacturing rules.

    High risk
  18. PLZ Corp

    FDA warned PLZ Corp over an OTC talc drug made in Mississauga without asbestos testing and with deficient component controls.

    High risk
  19. Asanuma Corporation - Sagamihara Factory

    FDA warned Japan's Asanuma Sagamihara factory, an OTC drug maker, that its talc was never tested for asbestos.

    High risk
  20. Shantou Qiwei Industry Co., LTD

    FDA warns Shantou Qiwei, a Chinese OTC drug maker, that it never tested talc for asbestos, making its products adulterated.

    High risk
  21. Zydus Lifesciences Limited

    FDA warns Zydus Lifesciences over untested asbestos in talc used in its prescription drugs and altered lab data at its Himachal Pradesh plant.

    High risk
  22. Macau-Union Pharmaceutical Limited

    Macau-Union Pharmaceutical failed CGMP and sold unapproved, misbranded Bamboo Pharmacy OTC pain rubs in the U.S.

    High risk
  23. Medline Inc

    FDA warned Medline Inc about repeated Bacillus cereus contamination in its drug products and inadequate investigations.

    High risk
  24. Laboratorios Jaloma S.A. de C.V.

    FDA found Laboratorios Jaloma’s OTC drug lab records were inaccurate, microbial tests unvalidated, and electronic data missing or uncontrolled.

    High risk
  25. Aeroflex Industria de Aerosol Ltda.

    Brazil OTC drug maker Aeroflex ignored FDA records requests, prompting possible approval holds and US shipment refusals.

    High risk
  26. Aversa's Italian Bakery

    FDA warns Aversa's Italian Bakery over missing food safety plan and undeclared sesame/milk allergens in ready-to-eat rolls.

    High risk
  27. Meta Labs Pharmaceuticals, LLC

    FDA warns Meta Labs its supplements are unapproved drugs and have serious manufacturing violations.

    High risk
  28. City Market, Inc.

    FDA cited City Market, Inc. for insanitary conditions and seafood safety plan (HACCP) failures involving ready-to-eat pasteurized canned crab meat.

    High risk
  29. Dough-To-Go, Inc.

    FDA warned Dough-To-Go of Santa Clara, CA after an inspection found insanitary conditions and unused food safety controls at its baked goods plant.

    High risk
  30. Stavis Seafoods, LLC

    FDA warned Stavis Seafoods that it lacked a required check for imported frozen aquaculture salmon fillets, making them adulterated.

    High risk
  31. Alchymars ICM SM Private Limited

    FDA found Alchymars API manufacturing had poor equipment and facility maintenance, making its APIs adulterated and prompting an import alert.

    High risk
  32. Sato Pharmaceutical Co., Ltd.

    FDA says Sato Pharmaceutical's sterile OTC drug line had contamination and stability failures.

    High risk
  33. GC America, Inc.

    FDA warned GC America after an inspection found inadequate component testing, stability data, and quality oversight for its OTC drugs.

    High risk
  34. Best Buy Bones, Inc.

    Best Buy Bones pet treats were found with Salmonella and serious animal-food safety and CGMP violations.

    High risk
  35. Shineluck Foods, Inc.

    FDA warns Shineluck Foods that its mung bean sprouts were held under insanitary conditions with pathogen testing and monitoring failures.

    High risk
  36. Harbin Jixianglong Biotech Co., Ltd.

    FDA warned Harbin Jixianglong Biotech over CGMP (manufacturing quality rules) failures and misbranded relabeled semaglutide API with false manufacturer labels and missing drug listings.

    High risk
  37. Hangzhou Yiqi Biotechnology Co., Ltd

    FDA cited Hangzhou Yiqi Biotechnology, an API maker in China, for four manufacturing practice failures found in a records review.

    High risk
  38. JW Nutritional LLC

    FDA warns JW Nutritional over serious CGMP failures in OTC drug manufacturing, including untested components and inadequate microbial limits.

    High risk
  39. IDO Pharm Co., Ltd.

    IDO Pharm, South Korean drug manufacturer, cited for good manufacturing practice violations including unvalidated system and test methods.

    High risk
  40. Naveh Pharma LTD/Bigdam Inc.

    FDA says Naveh Pharma and Bigdam sell unapproved saline drug products in the U.S. and have no quality unit.

    High risk
  41. Minh Phung, Inc.

    FDA warns Minh Phung, Inc. over insanitary conditions and time-temperature abuse in refrigerated rice noodles and rice cakes.

    High risk
  42. Ridley USA Inc.

    Ridley USA's Iowa City medicated feed plant put monensin into cattle feed instead of the intended drug, killing at least 16 cattle.

    High risk
  43. CareFusion 213, LLC

    FDA warns CareFusion 213 over inadequate investigations and contamination controls at its El Paso sterile drug plant.

    High risk
  44. Active Cosmetics Manufacturing Inc.

    FDA cited Active Cosmetics Manufacturing for releasing topical OTC drugs after microbial contamination without thorough investigations.

    High risk
  45. Respilon Production S.R.O.

    FDA found Respilon, a Czech OTC drug maker, lacked ingredient identity testing, stability data and process validation.

    Medium
  46. Ava Inc.

    FDA warned Ava Inc. about adulterated drugs after an inspection found data-integrity failures and hidden trial injections in its Willowbrook, Illinois lab.

    High risk
  47. Nature’s Elements, Inc.

    Nature's Elements sold supplement powders with disease claims as unapproved drugs and made them with no required manufacturing records, FDA says.

    High risk
  48. DO&CO Aktiengesellschaft/DO&CO, Inc.

    DO&CO airline catering facilities in New York and Michigan had repeated Listeria monocytogenes contamination and sanitation failures.

    High risk
  49. Hearthy Foods, Inc.

    FDA cited Hearthy Foods after an inspection for CGMP violations in RTE whey protein and dietary supplements, including allergen and pest issues.

    High risk
  50. South Bay Cold Storage & Handling, Inc.

    FDA warned South Bay Cold Storage & Handling that its seafood safety plans and sanitation were inadequate for crab, smoked salmon and scombroid fish.

    High risk